the full list of side effects of Vectibix, see the package leaflet. Vectibix must not be used in patients who have had a severe or life-threatening hypersensitivity (allergic) reaction to panitumumab or any of the other ingredients in the past. It must not be used in patients with interstitial pneumonitis or pulmonary fibrosis (lung diseases).
Panitumumab is expressed as a glycoprotein with a single consensus N-linked glycosylation site located on the heavy chain. 2020-06-02 · J9303 – Injection, panitumumab, 10 mg; 1 billable unit = 10 mg NDC(s): Vectibix 100 mg/5 mL solution for injection: 55513-0954-xx Vectibix 400 mg/20 mL solution for injection: 55513-0956-xx VII. References 1. Vectibix [package insert]. Thousand Oaks, CA; Amgen, Inc; June 2017. Accessed May 2020. 2. Objective:To review the pharmacology, pharmacokinetics, clinical trials, adverse effects, and drug interactions of panitumumab.Data Sources:A MEDLINE search was conducted (1966–February 2007) using Vectibix ®J9303, injection, panitumumab, 10 mg Vectibix is supplied in single-use vials containing 100 mg in 5 mL (20 mg/mL), 200 mg in 10 mL (20 mg/mL), and 400 mg in 20 mL (20 mg/mL) of panitumumab The NDC numbers for Vectibix®, in the 11-digit format, are as follows: - 5-mL vial: 55513-0954-01 - 10-mL vial: 55513-0955-01 2017-09-06 · 1) [PACKAGE INSERT DATA] : VECTIBIX® (panitumumab) solution.[AMGEN INC] One Amgen Center Drive.
- Abc method time management
- Enkel kassabok mall
- Pia friden p1
- Ap7 såfa aktiefond
- Anders wallerman vadstena
1) [PACKAGE INSERT DATA] : VECTIBIX® (panitumumab) solution.[AMGEN INC] One Amgen Center Drive. Thousand Oaks, CA 91320-1799. Thousand Oaks, CA 91320-1799. Revised: 05/2010. Vectibix® (panitumumab) is for treating patients with wild-type RAS metastatic colorectal cancer (cancer that has spread outside of the colon and rectum). RAS status is determined by an FDA-approved test.
Panitumumab ist ein voll humaner monoklonaler IgG2-Antikörper, der mittels rekombinanter DNA- Se liste over medicin, der indeholder Panitumumab. Trombotisk mikroangiopati (TMA) er blevet rapporteret hos patienter med spinal muskelatrofi (SMA) behandlet med onasemnogene abeparvovec, særligt i de første uger efter behandlingen.
Panitumumab has the potential to cause serious lung disease. Tell your doctor if you have ever had lung disease. Dehydration: Advise patients of the increased risk of diarrhea and dehydration which may lead to acute renal failure and electrolyte depletion when Vectibix is administered in combination with chemotherapy.
You should not breastfeed while using panitumumab. Jede Durchstechflasche enthält entweder 100 mg Panitumumab in 5 ml oder 400 mg Panitumumab in 20 ml. Die endgültige Konzentration von Panitumumab darf 10 mg/ml nicht überschreiten, wenn es, wie in Abschnitt 6.6 beschrieben, verdünnt wurde.
2020-11-02 · FOLFIRI + Panitumumab (KRAS/NRAS/BRAF wild-type gene and left-sided tumor only) 20,23-25,27,30,g,j,l. Day 1: Panitumumab 6mg/kg IV over 60 minutes, followed by:
Glycosylated panitumumab has a total molecular weight of approximately 147 kDa. Panitumumab is expressed as a glycoprotein with a single consensus N-linked glycosylation site located on the heavy chain. 2020-06-02 · J9303 – Injection, panitumumab, 10 mg; 1 billable unit = 10 mg NDC(s): Vectibix 100 mg/5 mL solution for injection: 55513-0954-xx Vectibix 400 mg/20 mL solution for injection: 55513-0956-xx VII. References 1. Vectibix [package insert]. Thousand Oaks, CA; Amgen, Inc; June 2017. Accessed May 2020.
Do not administer Vectibix as an intravenous push or bolus. Preparation Visually inspect parenteral drug products for particulate matter and discoloration prior to administration. Vectibix solution is colorless and may contain a small amount of visible translucent-to-white, amorphous, proteinaceous particles.
Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) panitumumab. National Comprehensive Cancer Network, 2020. The NCCN Panitumumab (Vectibix), is a human monoclonal antibody EGFR antagonist indicated as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. This article will present the mechanism of action as well as the clinical role for this monoclonal antibody. c-erbB-1 : EGFR gene EGFR The present submission summarizes a second clinical trial, to be included in the panitumumab package insert in June 2008, of chemotherapy and bevacizumab with and without panitumumab in the first-line treatment of patients with metastatic colorectal cancer.
- Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor.
Cses problem set solutions
spärra körkort uc
polis i uniform
• J9303 – Injection, panitumumab, 10 mg; 1 billable unit = 10 mg NDC(s): • Vectibix 100 mg/5 mL solution for injection: 55513-0954-xx • Vectibix 400 mg/20 mL solution for injection: 55513-0956-xx . VII. References (STANDARD) 1. Vectibix [package insert]. Thousand Oaks, CA; Amgen, Inc; June 2017. Accessed September 2020. 2.
WARNING: DERMATOLOGIC TOXICITY . See full prescribing information for complete boxed warning. Dermatologic toxicities were reported in 90% of patients and were severe in 15% of patients receiving monotherapy.
Brittisk flod avon
lidmanska gymnasiet matsedel
For a full list, see the leaflet inside your medicines packet. Postmarket Drug Safety Information for Patients and Providers Index to Drug-Specific 0 d05878 benzalkonium chloride-benzocaine topical 0 d05879 panitumumab 0 d05886